EUCTR2008-008127-15-EE进行中（未招募）不适用
A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with pioglitazone (15 mg, 30 mg, or 45 mg) or linagliptin 5 mg once daily for 30 weeks, followed by blinded trial period on linagliptin 5 mg + pioglitazone 30 or 45 mg versus pioglitazone monotherapy 30 or 45 mg or linagliptin 5 mg for up to 54 weeks in type 2 diabetic patients with insufficient glycaemic control on diet and exercise
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,811
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Diagnosis of type 2 diabetes mellitus prior to informed consent
- •- Male and female patients with insufficient glycaemic control (HbA1c = 7.0 to =
- •10.5% at Visit 2) on diet and exercise alone, without oral antidiabetic drug therapy
- •within 10 weeks prior to start of the run-in period
- •- Age = 18 and = 80 years at start of screening
- •- BMI = 45 kg/m2 (Body Mass Index) at start of screening
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Uncontrolled hyperglycaemia with a confirmed glucose level > 240 mg/dl (> 13.3
- •mmol/l) after an overnight fast during screening or placebo run-in period
- •- Myocardial infarction within 6 months, stroke or TIA within 3 months prior to
- •informed consent
- •- Clinical evidence of active liver disease (e.g. jaundice) or the ALT level > 2.5 times
- •the upper limit of normal (according to pioglitazone label)
- •- Bariatric surgery, performed within the past 2 years prior to informed consent or
- •planned at the time of informed consent
- •- Gastrointestinal surgeries prior to informed consent that induce chronic
- •malabsorption
- •- Known hypersensitivity or allergy to the investigational products (linagliptin and/or
- •pioglitazone) or their excipients (including matching placebos)
- •- Contraindications to pioglitazone as defined in the local prescribing information (
- •- Treatment with gemfibrozil, montelukast, trimethoprim, or rifampicin
- •- Treatment with rosiglitazone, pioglitazone, GLP-1 analogues, or insulin within 3
- •months prior to informed consent
- •- Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to
- •informed consent
- •- Alcohol or drug abuse within the 3 months prior to informed consent or documented history of alcoholism
- •- Current treatment with systemic corticosteroids at time of informed consent or
- •change in dosage of thyroid hormones within 6 weeks prior to informed consent
- •- Participation in another trial with an investigational drug within 30 days prior to
- •informed consent
- •- Pre-menopausal women (last menstruation < 1 year prior to informed consent)
- •who are nursing or pregnant or are of child-bearing potential (i.e. not permanently
- •sterilised) and are not practicing a highly effective method of birth control
- •- Symptomatic gallbladder disease in the last six months
- •- Medical history of pancreatitis
- •- Patients with urinary bladder cancer or a history of urinary bladder cancer or uninvestigated macroscopic haematuria
- •- Any other contraindication or restriction for use of pioglitazone in accordance with the local prescribing information for pioglitazone
研究者
相似试验
进行中（未招募）
不适用
A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with pioglitazone (15 mg, 30 mg, or 45 mg) or linagliptin 5 mg once daily for 30 weeks, followed by a 54 week blinded trial period on linagliptin 5 mg + pioglitazone 30 or 45 mg versus pioglitazone monotherapy 30 or 45 mg or linagliptin 5 mg in type 2 diabetic patients with insufficient glycaemic control on diet and exercisetype 2 diabetes mellitusMedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2008-008127-15-LVBoehringer Ingelheim RCV Gmbh1,811
进行中（未招募）
1 期
A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with pioglitazone (15 mg, 30 mg, or 45 mg) or linagliptin 5 mg once daily for 30 weeks, followed by a blinded trial period on linagliptin 5 mg + pioglitazone 30 or 45 mg versus pioglitazone monotherapy 30 or 45 mg or linagliptin 5 mg for up to 54 weeks in type 2 diabetic patients with insufficient glycaemic control on diet and exerciseEUCTR2008-008127-15-GBBoehringer Ingelheim Limited1,800
进行中（未招募）
不适用
A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with pioglitazone (15 mg, 30 mg, or 45 mg) or linagliptin 5 mg once daily for 30 weeks, followed by a 54 week blinded trial period on linagliptin 5 mg + pioglitazone 30 or 45 mg versus pioglitazone monotherapy 30 or 45 mg or linagliptin 5 mg in type 2 diabetic patients with insufficient glycaemic control on diet and exerciseEUCTR2008-008127-15-DEBoehringer Ingelheim Pharma GmbH & Co. KG1,800
已完成
不适用
A double-blind, randomised parallel group study to compare the efficacy and safety of cefuroxime plus erythromycin in the treatment of patients with community-acquired pneumoniaRespiratory tract diseases: Other respiratory tract diseaseRespiratoryISRCTN47137942HS R&D Regional Programme Register - Department of Health (UK)
尚未招募
4 期
A randomised, double blind, parallel-group study of the oxidative stress lowering effect of simvastatin and atorvastatin.arteriosclerosis1001108210003216AtherosclerosisNL-OMON30464Vrije Universiteit Medisch Centrum60